Structure, which concentrates on metabolic diseases with a particular focus on obesity, unveiled the topline data for its GLP-1 drug aleniglipron. The weight-loss treatment was put through its paces ...

Structure Therapeutics stock (NASDAQ: GPCR) rocketed above 103% Monday, trading near $70, after the clinical-stage biotech released promising mid-stage results for its oral obesity drug, aleniglipron.

Structure Therapeutics is developing a daily GLP-1 receptor pill called aleniglipron. Structure Therapeutics' stock soared toward an 18-month high in early Monday trading, after mid-stage data for its ...

Hedge fund BVF increased its GPCR holding by 275,105 shares in the fourth quarter; the estimated trade value was $11.2 million based on quarterly average prices. Meanwhile, the quarter-end position ...

Structure Therapeutics' Phase 2 data for Aleniglipron show 16% weight loss at 44 weeks with strong tolerability and no safety ...

Casdin Capital sold 380,000 shares of Structure Therapeutics in the fourth quarter for an estimated $15.52 million. Meanwhile, the quarter-end position value actually increased by $38.18 million, ...

Shareholders were extremely pleased by the biotech's latest news from the lab. This concerned its pipeline weight-loss drug aleniglipron. Structure, which concentrates on metabolic diseases with a ...